SAFE OPIOID PRESCRIBING AND THE MATE ACT

A LEGAL AND CLINICAL FRAMEWORK FOR RESPONSIBLE CONTROLLED SUBSTANCE MANAGEMENT

APRNworld

SAFE OPIOID PRESCRIBING AND THE MATE ACT:

A LEGAL AND CLINICAL FRAMEWORK FOR RESPONSIBLE CONTROLLED SUBSTANCE MANAGEMENT

ANCC Accredited NCPD Hours: 1 hrs

Target Audience: RN/APRN

NEEDS ASSESSMENT

The opioid epidemic remains a major public health threat, with over **112,000 overdose deaths reported in the United States in 2023**, more than 75% involving opioids (CDC, 2024). Inappropriate opioid prescribing practices, lack of provider education, and inconsistent regulatory compliance have contributed to widespread misuse, addiction, and preventable mortality. At the same time, access to safe and effective treatment for pain and opioid use disorder (OUD) remains limited, particularly in rural and underserved communities.

In recognition of these challenges, the MATE Act was designed to eliminate barriers to treatment by removing the federal X-waiver requirement for prescribing buprenorphine and mandating a one-time, 8-hour training for all DEA-registered clinicians. However, many providers remain unaware of these changes or uncertain about how to implement safe prescribing practices. Additional challenges include unfamiliarity with risk assessment tools, inadequate use of Prescription Drug Monitoring Programs (PDMPs), lack of integration of multimodal pain strategies, and hesitancy in managing patients with co-occurring SUDs.

To close these gaps, structured education on the MATE Act, safe opioid prescribing, and ethical/legal compliance is critical. Providers

must be equipped not only with updated legal knowledge but also with clinical skills to ensure evidence-based, patient-centred, and equitable pain management.

OBJECTIVES

Upon successful completion of this module, participants will be able to:

- **Describe** the key provisions of the MATE Act and its implications for controlled substance prescribers.
- **Implement** best practices for opioid prescribing, including the use of PDMPs, informed consent, treatment agreements, and naloxone co-prescription.
- **Conduct** comprehensive pain and substance use assessments using validated tools.
- **Apply** non-opioid and multimodal strategies for managing pain in patients with or at risk for substance use disorders.
- **Navigate** legal and ethical responsibilities associated with prescribing controlled substances in both in-person and telemedicine settings.

GOALS

This module aims to improve healthcare providers' understanding and confidence in managing controlled substances by bridging knowledge gaps in opioid prescribing laws, ethics, and clinical best practices. It helps increase safe access to treatment, reduce overdose risks, and support patient safety through informed decision-making and compliance with the MATE Act. The module also focuses on fair and equitable care, especially for those with coexisting substance use disorders.

INTRODUCTION

The ongoing opioid crisis has significantly impacted public health, with opioid-related overdose deaths continuing to rise across the United States. In response to these challenges, the Medication Access and Training Expansion (MATE) Act was enacted in 2022 as a legislative effort to standardise and strengthen prescriber education related to substance use disorders (SUDs) and controlled substance prescribing. The MATE Act eliminates the outdated X-waiver, expands the prescriptive authority for buprenorphine, and mandates a one-time 8-hour training for all DEA-registered providers.

This module addresses the clinical, ethical, and regulatory dimensions of controlled substance prescribing, equipping healthcare professionals with evidence-based strategies to manage opioid therapy responsibly. Emphasis is placed on non-opioid pain management, risk mitigation tools (e.g., PDMPs, opioid agreements, naloxone co-prescribing), and legal compliance at both federal and state levels. By

fostering a deeper understanding of the MATE Act's provisions and the importance of patient-centred care, this module empowers providers to navigate the complexities of opioid stewardship safely, ethically, and legally.

INTEGRATING EVIDENCE-BASED NON-OPIOID AND MULTIMODAL PAIN MANAGEMENT STRATEGIES IN PATIENTS WITH COEXISTING SUBSTANCE USE DISORDERS (SUDS)

Effective pain management in patients with coexisting substance use disorders (SUDs) presents a unique challenge. Opioid therapy, while traditionally used for pain control, poses significant risks in this population, including relapse, misuse, and overdose. To address these concerns, a **biopsychosocial and multimodal approach** is essential, incorporating **non-opioid pharmacologic therapies**, **psychological interventions**, **physical rehabilitation**, and **complementary therapies** tailored to the individual's risk profile and recovery stage.

1. Patient-Centred and Collaborative Approach

- **Shared Decision-Making**:
  Involve patients in discussions about pain goals and treatment options. Emphasise safety, effectiveness, and long-term recovery.
- **Therapeutic Alliance**:
  Build trust without reinforcing opioid-seeking behaviour. Validate their pain and recognise the challenges of pain during SUD recovery.
- **Realistic Expectations**:
  Set achievable goals focused on functional improvement rather than complete pain elimination.

2. Comprehensive Assessment

- **Pain Evaluation**:
  Assess type, intensity, duration, location, aggravating/alleviating factors, and impact on function. Use tools like the Numeric Rating Scale or Brief Pain Inventory.
- **SUD History**:
  Identify substances used, duration, severity, past treatments, and current recovery phase.
- **Psychiatric Comorbidity**:
  Screen for depression, anxiety, PTSD—common in this population and often exacerbate both pain and addiction.
- **Psychosocial Factors**:
  Assess trauma history, social support, housing, employment, and environmental stressors.

3. Prioritise Functional Restoration

- Shift focus from pain intensity to **quality of life**, daily function, and re-engagement in meaningful activities.
- Set **SMART goals** for sleep, physical activity, work participation, and recovery-oriented behaviours.

4. Minimising and Managing Opioid Exposure

- **Avoid New Opioids**:
  Avoid initiating opioids for new pain complaints unless necessary.
- **Opioid Tapering**:
  If on chronic opioid therapy, taper gradually under medical supervision. Integrate Medication-Assisted Treatment (MAT) where indicated.
- **MAT Integration**:
  Utilise buprenorphine, methadone, or naltrexone to stabilise OUD while managing pain. Additional analgesics may be needed, with caution.

EVIDENCE-BASED MULTIMODAL PAIN MANAGEMENT STRATEGIES

A. Pharmacologic (Non-Opioid) Approaches

Agent	Role	Mechanism	Consideration SUD
NSAIDs	First-line for musculo-skeletal/ inflammatory pain	Inhibit prostaglandins	Monitor for GI, renal, CV risks; caution in alcohol use
Acetaminophen	Mild to moderate pain	Central analgesic	Avoid hepatotoxicity; monitor in patients with liver disease or AUD
Antidepressants (TCAs, SNRIs)	Neuropathic pain, fibro-myalgia, and co-occurring depression	Modulate serotonin/nore pinephrine	Low abuse potential; monitor cardiac, sedation effects
Anticonvulsants (Gabapentin, Pregabalin)	Neuropathic pain, fibro-myalgia	Modulate calcium channels	Caution in patients with polysubstance use; monitor for sedation
Topical Agents	Localized pain	Local anti-inflammatory or anaesthetic	Minimal systemic effects; low abuse potential

B. Physical and Movement-Based Therapies

Therapy	Role	Benefits for SUD patients
Physical Therapy (PT)/Occupational Therapy (OT)	Improve mobility, posture, and self-management	Promotes structure, function, and self-efficacy
Exercise Programs	Foundational strategy	Enhances mood, sleep, and coping; reduces cravings
Yoga & Tai Chi	Mind-body movement therapies	Improve balance, stress reduction, and mindfulness

C. Psychological and Behavioural Therapies

Therapy	Role	Benefits for SUD patients
Cognitive Behavioural Therapy (CBT)	Restructure pain-related thoughts and behaviours	Addresses maladaptive coping, enhances pain control
Mindfulness-Based Stress Reduction (MBSR)	Enhances awareness, reduces pain reactivity	Reduces emotional distress and supports relapse prevention
Acceptance and Commitment Therapy (ACT)	Accept pain, commit to values-based actions	Reduces avoidance and disability, fosters resilience

D. Integrative and Complementary Approaches

Therapy	Evidence	Consideration for SUD
Acupuncture	Moderate to strong for specific pain syndromes	Safe, non-addictive, supports holistic care
Massage Therapy	Short-term relief of muscle tension	Enhances relaxation and well-being
Nutritional Support	Anti-inflammatory diets, correct deficiencies	Supports systemic health and recovery
Sleep Hygiene & Relaxation Techniques	Support for restorative sleep	Reduce hyperarousal and pain sensitivity

INTEGRATED CARE AND INTERDISCIPLINARY COLLABORATION

- **Team-Based Care**:
  Involve primary care, addiction specialists, psychiatrists, therapists, PTs/OTs, and case managers.
- **Regular Case Conferences**:
  Promote shared care plans, track outcomes, and adjust treatments collaboratively.
- **Referral Networks**:
  Streamlined access to pain clinics, SUD recovery centres, mental health services.
- **Clear Communication**:
  Ensure consistent messaging across providers, especially in transitions of care.
- **Patient Empowerment**:
  Equip patients with education, coping tools, and recovery-focused planning.

A multimodal, non-opioid, and **integrated approach to pain management** in patients with coexisting SUD acknowledges the complex interplay of biological, psychological, and social factors in pain. It also minimises the risk of opioid-related harms, supports recovery, and promotes **functional improvement and quality of life**. Through **collaborative care, patient engagement, and evidence-based interventions**, healthcare providers can effectively manage chronic pain without compromising addiction recovery.

SAFE OPIOID PRESCRIBING PRACTICES: A PROFESSIONAL FRAMEWORK FOR RISK MITIGATION AND PATIENT SAFETY

Safe opioid prescribing is a critical imperative in modern pain management, particularly in the context of the ongoing global opioid crisis and the prevalence of substance use disorders (SUDs). It demands a structured, evidence-based, and patient-centred approach designed to minimise the inherent risks of misuse, dependence, overdose, and diversion, while ensuring appropriate and effective pain control. This framework integrates best practices grounded in current evidence and guidance from leading health organisations.

1. Comprehensive Risk Assessment

Before initiating or continuing opioid therapy, a meticulous and ongoing risk assessment is fundamental.

- **Holistic Patient Evaluation:**
  - **Medical History:** Thoroughly assess the pain condition, including its aetiology, severity, duration, functional impact, and previous treatment modalities.
  - **Substance Use History:** Conduct universal screening for current or past use, misuse, or diagnosis of SUD (including alcohol, tobacco, and illicit drugs). This should involve direct questioning and potentially collateral information.
  - **Mental Health Screening:** Systematically identify co-occurring psychiatric conditions (e.g., depression, anxiety, PTSD), which are prevalent in chronic pain populations and can significantly escalate the risk of opioid misuse and poorer outcomes.
- **Validated Screening Tools:** Utilise standardised, evidence-based tools to objectively stratify risk for opioid-related harm:
  - **Opioid Risk Tool (ORT):** A concise 5-item questionnaire assessing personal and family history of substance abuse and psychiatric disorders.
  - **Screener and Opioid Assessment for Patients with Pain (SOAPP-R):** A more comprehensive tool to predict aberrant drug-related behaviours.
  - **Drug Abuse Screening Test (DAST-10):** While not opioid-specific, it screens for problematic non-opioid drug use.
  - **Mental Health Screens:** Tools like PHQ-9 (for depression) and GAD-7 (for anxiety) are essential.
- **Clinical Evaluation & Stratification:** Synthesise information from patient history, collateral sources, and screening tools to

stratify patients into low, moderate, or high-risk categories for opioid misuse. This stratification informs the intensity of monitoring and the specific mitigation strategies employed.

- **Baseline Urine Drug Screening (UDS):** Conduct a baseline UDS to confirm the presence of prescribed medications and detect undisclosed illicit substance use, as well as prescribed non-opioid controlled substances.

2. Establishment of Treatment Agreements (Pain Contracts)

Formal written treatment agreements are crucial for setting clear expectations, fostering patient accountability, and enhancing communication.

- **Essential Components:**
  - **Designated Prescriber and Pharmacy:** Commitment to obtain all opioid prescriptions from a single prescriber and dispense them at a single pharmacy.
  - **Adherence to Regimen:** Strict adherence to prescribed dosage, frequency, and route of administration, with no unauthorised dose escalation or early refills.
  - **Monitoring Compliance:** Consent to periodic, often random, urine drug screening and pill counts.
  - **Prohibited Behaviours:** Explicit prohibition of sharing, selling, or diverting medication; obtaining opioids from other sources; or using illicit substances.
  - **Consequences of Non-Compliance:** Clear outline of actions that will be taken if the agreement is violated, ranging from dose adjustment to discontinuation of opioid therapy and referral to specialised care.
  - **Safe Storage and Disposal:** Instructions on secure storage (e.g., in a locked cabinet) and proper disposal of unused medication to prevent accidental ingestion or diversion.
- **Patient Education:** Thoroughly review the agreement with the patient, ensuring full understanding of its terms, the rationale behind it, and the potential consequences of non-adherence. While evidence for direct reduction of misuse is mixed, these agreements undeniably improve patient-provider communication and define boundaries.

3. Naloxone Co-Prescribing

Providing access to naloxone is a life-saving intervention and a standard of care for patients at elevated risk of opioid overdose.

- **Indications for Co-Prescribing:**

- Patients receiving high-dose opioid therapy (≥50 Morphine Milligram Equivalents (MME) per day).
- Concurrent use of benzodiazepines or other Central Nervous System (CNS) depressants.
- History of opioid overdose or documented substance use disorder (OUD/SUD).
- Presence of respiratory conditions (e.g., COPD, sleep apnoea).
- Household members (e.g., children, other individuals with SUD) who may be at risk of accidental exposure or intentional misuse.

- **Patient and Caregiver Education:**
  Comprehensive education is vital and should include:
  - Recognition of opioid overdose signs (e.g., unresponsiveness, slow/absent breathing, constricted pupils).
  - Detailed instructions on how to administer naloxone (intranasal spray or intramuscular injection).
  - Emphasis on the critical importance of calling emergency services (911/emergency contact in India) immediately after naloxone administration, as the effects are temporary and further medical attention is required.
- **Formulations:**
  Utilise readily available and user-friendly formulations such as intranasal naloxone spray (e.g., 4 mg/dose) or intramuscular autoinjectors.

4. Periodic Review and Monitoring

Ongoing monitoring is essential to ensure the continued appropriateness of opioid therapy and to detect potential problems early.

- **Regular Reassessment:**
  - During Initiation/Dosage Changes: Increase patient contact during the initiation phase and with any changes to dosage or agent.
  - Ongoing Monitoring: Regularly reassess for changes in pain origin, health status, and functional improvement. This can involve input from family members.
  - **"5A's" monitoring: Systematically assess the "5A's" at every side:**
    - Analgesia: Pain relief achieved
    - Activities of daily living: Improvement in function
    - Adverse or Side effects: Presence and Severity
    - Aberrant Drug-related behaviours: Any sign of misuse or diversion
    - Affect: Patient's mood and psychological state
  - **Warning Signs:**
    Be vigilant for problematic

responses such as excessive sleeping, diminished appetite, short attention span, mood volatility, impaired functioning due to drug effects, lack of involvement, or poor hygiene.

- **Objective Monitoring Tools:**
  - **Urine Drug Tests (UDTs):**
    - Frequency: Conduct baseline UDT before starting opioids and consider at least annually for all patients. Higher risk patients and those in addiction therapy require more frequent testing (e.g., every 3-6 months for high risk, every 6-12 months for medium risk, every 1-2 years for low risk).
    - Methodology: Initially use class-specific immunoassay panels; confirm abnormalities with confirmatory testing (e.g., gas chromatography/ mass spectrometry) to identify specific drugs and metabolites. Ensure the prescribed opioid is included in the screen.
    - Discussion: Discuss abnormal results with the patient using a supportive approach and document the discussion.
  - Pill Counts:
    Periodically perform pill counts to confirm adherence and minimise diversion.
  - Family Involvement:
    Engage family members (with patient consent) for valuable insights into functional changes, behavioural patterns, and potential problematic responses to opioid therapy.

5. Opioid Tapering Protocols

Tapering opioids is a necessary and responsible practice when clinical circumstances warrant a reduction or discontinuation of therapy.

- **Indications for Tapering:**
  - Lack of significant pain relief or functional improvement from continued opioid use.
  - Development of unacceptable adverse effects.
  - Evidence of aberrant drug-related behaviours or misuse.

- Transition to more effective non-opioid pain management strategies.
- Patient request for discontinuation.
- Resolution of the underlying painful condition.

- **Key Principles for Safe Tapering:**
  - **Individualised Plan:** Develop a tapering schedule tailored to the individual patient's stability, current opioid dose, duration of therapy, co-morbid conditions, and preferences. Avoid "one-size-fits-all" approaches.
  - **Slow and Gradual Reduction:** Generally, reduce the dose by 10% per week to 10% per month, allowing for slower tapers in long-term, high-dose patients to minimise withdrawal. Pause or slow the taper if severe withdrawal symptoms or significant functional deterioration occur.
  - **Supportive Measures:**
    - **Adjunctive Medications:** Prescribe non-opioid medications to manage withdrawal symptoms (e.g., clonidine for adrenergic symptoms, NSAIDs for body aches, antiemetics for nausea).
    - **Psychosocial Support:** Provide or refer to behavioural therapies (e.g., CBT, ACT), counselling, and peer support to help patients cope with the physical and psychological challenges of tapering.
    - **Medication-Assisted Treatment (MAT):** For patients who develop OUD during opioid tapering, or those with pre-existing OUD, offer MAT (e.g., buprenorphine) to manage withdrawal and prevent relapse.
  - **Communication:** Maintain open and empathetic commu - nication with the patient throughout the tapering process.

6. Utilisation of Prescription Drug Monitoring Programs (PDMPs)

PDMPs are indispensable electronic databases that track controlled substance prescriptions and are fundamental tools for prescribers. In India, while a centralised nationwide PDMP equivalent is still evolving, clinicians should utilize any available state-level or regional electronic tracking systems.

- **Mandatory Checks:** Review PDMP data (or equivalent local systems) *before* initiating any new opioid prescription and at regular intervals (e.g., quarterly or more frequently for high-risk patients) throughout therapy.
- **Purpose and Insights:**
  - **Identify Risky Patterns:** Detect "doctor shopping" (patients obtaining prescriptions from multiple

prescribers), multiple concurrent controlled substance prescriptions (e.g., opioids and benzodiazepines), early refills, or unusually high-dose prescriptions.

- **Inform Clinical Decisions:** Provide objective data to confirm patient adherence to the prescribed regimen, assess overall risk, and guide decisions on initiating, continuing, or adjusting opioid therapy.

- **Best Practices:**
  - **Integrate into Workflow:** Streamline PDMP checks into routine clinical workflows and electronic health records (EHRs).
  - **Document Findings:** Meticulously document PDMP findings and any subsequent clinical actions or discussions with the patient in the medical record.
  - **Combined Use:** Utilise PDMP data in conjunction with UDS results to obtain a comprehensive picture of patient adherence and potential illicit drug use.

7. Consultation and Referral

- Specialist Consultation: Seek input or refer to pain, psychiatry, addiction, or mental health specialists when complex issues arise or when their expertise is required.
- Addiction Treatment Resources: Clinicians should be familiar with local opioid addiction treatment options, including licensed Opioid Treatment Programs (OTPs) for methadone and office-based buprenorphine treatment, for referral.
- Co-Management for SUD: If active substance abuse is present, consult an addiction specialist. Avoid prescribing opioids until the patient is engaged in a treatment/recovery program or co-managed by an addiction professional with additional monitoring.
- Pain Management in OUD Patients on MAT:
  - **Buprenorphine:** For acute pain, consider temporarily increasing buprenorphine dosing frequency. For severe acute pain, consider additional as-needed buprenorphine doses or, in supervised settings, cautiously adding a short-acting full agonist opioid without discontinuing buprenorphine. Close monitoring is crucial.
  - **Naltrexone:** Patients on naltrexone will not respond to opioid analgesics. Manage acute pain with higher-potency non-opioid analgesics (e.g., NSAIDs, regional blocks).

- **Methadone:** Patients on methadone requiring additional opioids for severe acute pain should be carefully monitored, ideally in consultation with their OTP provider.

8. Medical Records and Documentation

Accurate, complete, and up-to-date medical records are non-negotiable for both healthcare quality and medico-legal protection.

- **Comprehensive Documentation**:
  Record all opioid prescription orders, patient instructions, pharmacy information, and all aspects of assessment, monitoring, and decision-making.
- **Pain Assessment and Documentation Tool (PADT)**:
  Consider using structured tools like the PADT to address documentation shortcomings, ensuring systematic recording of analgesia, activities of daily living, adverse events, aberrant drug-related behaviours, and affect.

9. Patient Education on Safe Use and Disposal

Comprehensive education for patients and caregivers on safe use, storage, and disposal of opioids is paramount.

- Key Information to Provide:
  - Product-specific details, including proper administration and managing missed doses.
  - Warnings against breaking, chewing, or crushing tablets, or cutting/tearing patches.
  - Warning to avoid other CNS depressants (sedative-hypnotics, anxiolytics, alcohol, illicit drugs).
  - Rationale for not abruptly halting or reducing opioids without physician oversight.
  - Potential for serious side effects, overdose, and opioid-induced respiratory depression.
  - Risks associated with falls, driving, and operating heavy machinery.
  - Absolute warning against sharing or selling opioids.
  - Secure Storage: Emphasise the importance of secure storage (e.g., in a locked cabinet, away from damp/moist environments like bathrooms) to prevent accidental ingestion or theft.
  - Disposal Instructions: Provide clear, product-specific instructions for the disposal of unneeded/expired opioids. This may include mixing with undesirable substances and placing in an impermeable container for trash, or flushing certain medications down the toilet *only if explicitly instructed on the label by*

the FDA. Refer patients to community "take-back" programs where available (e.g., through law enforcement agencies).

- "Remove the Risk" Toolkit: Leverage FDA resources like the "Remove the Risk Outreach toolkit" for patient education materials.

10. Considerations for Non-English-Proficient Patients

- **Language Access:**
  Provide information regarding opioid risks and available resources in the patient's native language whenever possible.
- **Professional Interpreters:**
  Utilise qualified interpreters to bridge communication and cultural gaps, especially when discussing treatment options, medication use, and potential risks. Interpreters should be considered integral to the interdisciplinary clinical team.

By rigorously applying these comprehensive safe opioid prescribing practices, clinicians can navigate the complexities of chronic pain management effectively while proactively mitigating the substantial risks associated with opioid therapy.

ADDITIONAL BEST PRACTICES

- Start Low and Go Slow:
  Always begin with the lowest effective opioid dose for the shortest duration necessary, especially for acute pain.
- Prefer Short-Acting Over Long-Acting (IR over ER/LA): For acute pain, prioritise immediate-release (IR) opioids. Avoid extended-release/long-acting (ER/LA) opioids in opioid-naïve patients due to higher risks.
- Avoid Concurrent Benzodiazepine Use:
  Co-prescribing opioids and benzodiazepines significantly increases the risk of severe respiratory depression and overdose. If necessary, extreme caution, reduced doses of both medications, and robust patient education (including naloxone co-prescribing) are paramount.
- Regular Reassessment:
  Periodically reassess pain control, functional status, adverse effects, adherence, and the overall goals of therapy. Initial reassessments may be every 1–4 weeks, extending to every 3–6 months for stable patients. Taper or discontinue opioids if the harms outweigh the benefits.

Safe opioid prescribing is not about denying access to necessary pain relief but about fostering responsible, judicious, and evidence-informed practice. A structured approach encompassing comprehensive risk assessment, clear treatment agreements, universal naloxone

co-prescription for at-risk individuals, individualised tapering protocols, and vigilant utilisation of PDMPs enables clinicians to manage pain effectively while profoundly minimising the risks of misuse, diversion, and overdose, thereby protecting both the individual patient and public health

MEDICATION ACCESS AND TRAINING EXPANSION (MATE) ACT: KEY PROVISIONS, SAFE PRESCRIBING PRACTICES, AND CLINICAL IMPLICATIONS

The Medication Access and Training Expansion (MATE) Act, enacted through the Consolidated Appropriations Act of 2023, is a pivotal step in addressing the opioid crisis in the United States. It aims to expand access to medications for opioid use disorder (MOUD), standardise safe prescribing practices, and equip healthcare providers with essential knowledge on substance use disorders (SUDs). This summary outlines the Act's key provisions, DEA/state-specific requirements, telemedicine regulations, and clinical implications for practice.

I. Key Provisions of the MATE Act (and related MAT Act)

1. Elimination of the DATA 2000 X-Waiver

- **Provision:**

  The MAT Act, enacted as part of the Consolidated Appropriations Act of 2023, effectively repealed the Drug Addiction Treatment Act of 2000 (DATA 2000) X-waiver requirement. This waiver previously mandated specific training and a separate DEA registration number (beginning with "X") for practitioners to prescribe buprenorphine for opioid use disorder (OUD) in an office-based setting.
- **Effect (from December 29, 2022):**
  - **Expanded Prescribing Authority:**

    Any DEA-registered practitioner authorised to prescribe Schedule III controlled substances (which typically includes most physicians, nurse practitioners, and physician assistants with general prescribing authority) can

now prescribe buprenorphine for OUD without needing the additional X-waiver certification. This means the standard DEA registration number is now sufficient for buprenorphine prescriptions for OUD.

- **Removal of Patient Caps:** The federal patient limits that previously restricted the number of patients a waivered practitioner could treat with buprenorphine (e.g., 30, 100, or 275 patients) have been eliminated. Practitioners are now federally authorized to treat any number of patients with buprenorphine for OUD, within the bounds of their clinical judgment and state scope of practice.
- **No Additional Federal Certifications:** The former federal requirements for specific counselling provisions or discipline restrictions tied to the X-waiver are no longer in effect.

- **Impact:**
  - **Dramatically Increases Access to OUD Treatment:** This is the most profound impact. The X-waiver was widely recognised as a significant barrier to OUD treatment access, particularly in primary care settings and rural areas where speciality addiction providers are scarce. By removing this administrative hurdle, the number of clinicians federally authorised to prescribe buprenorphine jumped from approximately 130,000 to potentially 1.8 million (all DEA-registered prescribers).
  - **Evidence of Increased Access:** As cited, SAMHSA (Substance Abuse and Mental Health Services Administration) has reported a substantial rise (e.g., 53% in some reports) in patients receiving buprenorphine since the X-waiver repeal, indicating a positive initial trend towards expanded access.
  - **Mainstreaming OUD Treatment:** The elimination of the X-waiver signifies a shift towards integrating OUD treatment into mainstream medical practice. It sends a powerful message that OUD is a medical condition that can and should be treated like other chronic diseases, reducing the historical stigma associated with both the condition and its medication-assisted treatment.
  - **Potential for Improved Outcomes:** Increased access to buprenorphine, a highly effective medication shown to reduce overdose deaths and curb illicit opioid use, is anticipated to contribute to a reduction in opioid overdose fatalities and improved recovery rates.
  - **Simplification for Clinicians:**

Prescribers no longer need to navigate a separate application process or manage a second DEA number, simplifying the administrative burden for those wishing to treat OUD.

- **Challenges/Considerations:**
  - **State Law Variability:**
    While federal law has changed, practitioners must still be aware of and comply with their specific state's laws and regulations regarding buprenorphine prescribing, as some states may have retained or introduced their requirements.
  - **Need for Continued Training and Support:**
    While the X-waiver's *mandatory* training is gone, the MATE Act introduces a new, broader training requirement (discussed separately) that aims to equip all controlled substance prescribers with foundational knowledge in SUDs. However, ongoing education, clinical confidence, and access to mentorship/support for managing complex OUD cases remain crucial for widespread adoption and effective treatment.
  - **Stigma Persistence:**
    While the federal policy change aims to reduce stigma, ingrained biases among some clinicians, patients, and pharmacies may persist, requiring continued educational efforts and advocacy.
  - **Pharmacy Access:**
    Issues with pharmacy stock, wholesaler monitoring systems, and occasional pharmacist hesitancy to fill buprenorphine prescriptions for OUD remain challenges that require ongoing attention from regulatory bodies.
  - **Integration of Behavioural Health:**
    While buprenorphine is highly effective, optimal OUD treatment often involves integrated behavioural health support. The elimination of patient caps allows for broader prescribing but emphasises the need for systems that can provide comprehensive care.

2. Mandatory One-Time 8-Hour SUD Training

- **Provision:**
  The MATE Act mandates that all Drug Enforcement Administration (DEA)-registered practitioners (with the sole exception of veterinarians) must complete a **one-time, minimum of 8 hours of accredited training** focused on the treatment and management of patients with opioid or other substance use disorders, and/or the safe pharmacological management of dental pain. This requirement took effect on **June 27, 2023**.

- **Who it Applies To:**
  This applies to nearly all clinicians who prescribe controlled substances under a DEA registration, including:
  - Physicians (MDs, DOs)
  - Nurse Practitioners (NPs)
  - Physician Assistants (PAs)
  - Dentists (DDS, DMD)
  - Any other DEA-registered practitioner authorised to prescribe controlled medications.
- **When the Requirement Must Be Met:**
  The 8-hour training must be completed *before* a practitioner applies for a new DEA registration or renews an existing one on or after **June 27, 2023**. This is a **one-time** requirement; once satisfied and attested to, it does not need to be repeated for subsequent DEA registration renewals (which typically occur every three years). This means a practitioner who renewed their DEA license just before June 27, 2023, might have until their next renewal cycle (e.g., in 2026) to complete the training.
- **Accepted Training Pathways (Flexibi - lity in Fulfilment):**
  The MATE Act offers considerable flexibility in how practitioners can fulfil this 8-hour requirement, acknowledge prior learning and provide multiple avenues for new training:
  - **Prior X-Waiver Training:**
    Any practitioner who previously completed the 8 hours of training required for the DATA 2000 X-waiver to prescribe buprenorphine for OUD is considered to have satisfied this new requirement. This means their past efforts are recognised and count towards the MATE Act.
  - **Board Certification in Addiction Specialties:**
    Practitioners who are already board-certified in addiction medicine or addiction psychiatry by recognized bodies such as the American Board of Medical Specialties (ABMS), the American Board of Addiction Medicine (ABAM), or the American Osteopathic Association (AOA) are exempt from this new training, as their existing certification demonstrates a high level of expertise in SUDs.
  - **Recent Graduates:**
    Practitioners who graduated in good standing from a U.S. medical, dental, physician assistant, or advanced practice nursing school within **five years of June 27, 2023**, are exempt, provided their curriculum included at least 8 hours of relevant SUD coursework. This acknowledges that many modern health professional programs already integrate robust SUD education.

- **Accredited Continuing Medical Education (CME)/Continuing Edu - cation (CE):**

  The most common pathway for many practitioners will be the completion of 8 hours of accredited CME or CE from organisations accredited by:

  - Accreditation Council for Continuing Medical Education (ACCME)
  - American Medical Association (AMA)
  - American Academy of Family Physicians (AAFP)
  - American Academy of Physician Assistants (AAPA)
  - American Nurses Credentialing Centre (ANCC)
  - American Dental Association (ADA)
  - American Psychiatric Association (APA)
  - American Society of Addiction Medicine (ASAM)
  - Substance Abuse and Mental Health Services Administration (SAMHSA)
  - Other organisations recognised by the DEA or SAMHSA. Importantly, this training does **not** need to be completed in one single 8-hour session; it can be cumulative across multiple courses, activities, or sessions that collectively total at least 8 hours.

- **Format:**

  The training can be completed in various formats, offering convenience and accessibility:

  - **Live:**

    In-person conferences, workshops, or seminars.
  - **Virtual (Live Webinars):**

    Real-time online sessions.
  - **Self-Paced/Enduring Material:**

    Online modules, recorded webinars, or self-study courses that can be completed at the practitioner's convenience.

- **Content Focus:**

  The training content should cover a broad range of topics related to SUDs, including:

  - Prevention of SUDs.
  - Recognition and screening for SUDs (including opioid, alcohol, and other substance use disorders).
  - Assessment and diagnosis of SUDs.
  - Evidence-based treatment and management strategies for SUDs, including pharmacologic (e.g., all FDA-approved medications for SUDs) and non-pharmacologic interventions.
  - Management of co-occurring conditions, such as chronic pain and psychiatric disorders, in patients with SUDs.
  - Appropriate prescribing practices for controlled substances, including risk

mitigation strategies (e.g., PDMPs, UDTs, informed consent).
    - Confidentiality rules (e.g., HIPAA and 42 CFR Part 2) related to SUD patient records.
    - Addressing health disparities and biases in SUD care.
- **Attestation and Documentation:**
    - **Attestation:** Practitioners will attest to having completed the training by checking a box on their online DEA registration or renewal application form.
    - **No Upfront Submission:** Typically, practitioners do not need to submit their training certificates or proof of completion to the DEA unless specifically requested (e.g., in the event of an audit). However, it is strongly recommended that practitioners retain all records, certificates, and documentation of their completed training for their records and potential future verification.
- **Clinical Implications of the 8-Hour Training:**
    - **Increased Foundational Knowledge:** This universal training ensures that all prescribers of controlled substances have a baseline understanding of SUDs, regardless of their speciality. This equips them to better identify, screen for, and potentially intervene early in cases of substance misuse or addiction.
    - **Improved Patient Safety:** By increasing awareness of SUD risk factors, signs of misuse, and appropriate prescribing practices, the training aims to reduce iatrogenic addiction and overdose deaths.
    - **Better Pain Management:** The curriculum's emphasis on appropriate pain management in the context of SUDs promotes a balanced approach that reduces reliance on opioids where possible and encourages multidisciplinary pain care.
    - **Earlier Intervention and Referral:** A more educated workforce is better positioned to recognise SUDs in their patients and either initiate appropriate care (like buprenorphine for OUD) or make timely referrals to addiction specialists.
    - **Reduced Stigma:** By making SUD education a standard requirement for all controlled substance prescribers, the MATE Act further normalises the understanding and treatment of addiction as a medical condition, helping to break down stigma.

In essence, the MATE Act's 8-hour training requirement, coupled with the X-waiver repeal, signifies a concerted effort to empower the

broader healthcare workforce to play a more active and informed role in addressing the substance use crisis by improving clinical competency and expanding access to evidence-based treatments.

3. No Recurring Training Requirement

- **Provision:**
  This training is **one-time only** and does not need to be repeated at future DEA renewals.
- **Clinical Benefit:**
  Ensures all controlled substance prescribers have a **baseline SUD competency** without excessive regulatory burden.

II. DEA and State-Specific Prescribing Requirements

A. DEA Requirements: Foundational Principles for Controlled Substances

The Drug Enforcement Administration (DEA) sets the overarching federal framework for controlled substances, ensuring their legitimate medical use and preventing diversion.

- **Legitimacy of Prescription :**
  - **Core Principle:**
    This is the bedrock of all controlled substance prescribing. Every prescription for a controlled substance (across all schedules: II, III, IV, V) *must* be issued for a legitimate medical purpose by a practitioner acting in the usual course of their professional practice.
  - **Clinical Implication:**
    This places a significant responsibility on the prescriber to exercise sound medical judgment, conduct a thorough patient assessment, establish a bona fide patient-prescriber relationship, and ensure the prescription is medically necessary and appropriate for the patient's condition. It's not merely a technical requirement but a core ethical and legal obligation. Pharmacists also share a "corresponding responsibility" to ensure legitimacy before dispensing.
- **Registration Compliance:**
  - **Valid DEA Registration:**
    Prescribers must possess a valid and current DEA registration number specific to their practice location and the schedules of controlled substances they intend to prescribe. This registration is distinct from their state professional license.
  - **Federal and State Law Compliance:**
    Practitioners are obligated to comply with *both* federal (DEA) and all applicable state laws governing controlled substances. State laws can be, and often are, more stringent than federal requirements, creating a complex compliance landscape.

- **Telemedicine Specifics:**
  When prescribing controlled substances via telemedicine, prescribers must particularly adhere to specific federal and state laws. Historically, the **Ryan Haight Online Pharmacy Consumer Protection Act of 2008** generally required an in-person medical evaluation before prescribing controlled substances via telemedicine. During the COVID-19 Public Health Emergency, temporary waivers eased this, and the DEA is now developing **special registrations for telemedicine** to create a permanent framework for telemedicine prescribing of controlled substances without a prior in-person visit in certain circumstances. Critically, the prescriber must typically hold a DEA registration *in the state where the patient is located* during the telemedicine encounter, in addition to their state of practice, further complicating multi-state telemedicine.

B. MATE Act-Specific Requirements: Enhancing SUD Competency

The Medication Access and Training Expansion (MATE) Act (part of the Consolidated Appropriations Act of 2023) directly targets the substance use disorder crisis by mandating enhanced education for prescribers.

- **Attestation:**
  - **When Required:**
    As of **June 27, 2023**, all DEA-registered practitioners (excluding veterinarians) are required to attest to having completed a **one-time, 8-hour training** on opioid or other substance use disorders, and/or the safe pharmacological management of dental pain. This attestation is made when applying for a new DEA registration or renewing an existing one.
  - **Mechanism:**
    This is typically a checkbox on the DEA application form, signifying that the practitioner has fulfilled the educational requirement. No certificates are generally submitted unless requested for audit purposes.
  - **Clinical Implication:**
    This attestation serves as a federal mechanism to ensure a baseline competency in SUD care among nearly all controlled substance prescribers. It formalises a critical educational component that was previously inconsistent across the healthcare landscape. The "one-time" nature acknowledges that while ongoing learning is essential, this specific federal mandate is a foundational milestone.

- **Goal:**
  - **Dual Purpose:**

    The overarching goal of the MATE Act is twofold:

    1. **Expand Access to Evidence-Based SUD Treatment:**

       By mandating training and, in conjunction with the MAT Act, eliminating the buprenorphine X-waiver, the MATE Act seeks to significantly increase the number of healthcare professionals capable of diagnosing and treating SUDs, particularly OUD, thereby improving access to life-saving medications like buprenorphine.
    2. **Promote Safe Opioid Prescribing:**

       The training emphasises responsible prescribing practices, risk mitigation strategies (like PDMP use, urine drug testing, informed consent), and alternative pain management modalities, all aimed at reducing opioid misuse, diversion, and overdose while still ensuring appropriate pain care.
  - **Clinical Implication:** This goal signifies a national commitment to equipping general healthcare providers with the knowledge to address the opioid crisis from both the prevention (safe prescribing) and treatment (SUD management) perspectives, fostering a more integrated approach to care.

C. State Variability in Regulation: The Layered Compliance Landscape

While federal laws provide a baseline, individual states retain significant authority to impose additional or more stringent requirements for controlled substance prescribing. Clinicians *must* be intimately familiar with the laws of every state in which they practice and where their patients are located.

- **PDMP Mandates (Prescription Drug Monitoring Programs):**
  - **Purpose:**

    PDMPs are electronic databases that track controlled substance prescriptions. They are vital tools for identifying patients at risk of overdose or diversion ("doctor shopping").
  - **State-Specific Mandates:**

    Most states now mandate the use of their PDMP by prescribers before prescribing controlled substances, particularly opioids.
  - **Example (California's CURES):**

    California requires prescribers to check the Controlled Substance Utilisation Review and Evaluation System (CURES) database before prescribing a Schedule II, III, or IV

controlled substance, and periodically thereafter.

- **Example (New York's I-STOP):**
  New York's Internet System for Tracking Over-Prescribing (I-STOP) mandates checking the PDMP before prescribing Schedule II, III, IV, and V controlled substances, with very limited exceptions.
  - **Clinical Implication:**
    Failure to check the state's PDMP when required can result in disciplinary action from state licensing boards, fines, and even criminal charges. It's a critical step in risk assessment and diversion prevention.

- **Opioid Prescribing Limits:**
  - **Purpose:**
    Many states have enacted laws to limit the quantity or duration of initial opioid prescriptions, particularly for acute pain, to prevent oversupply and reduce the risk of dependence.
  - **State-Specific Limits:**
    These limits vary by state and often depend on the type of pain (acute vs. chronic) and whether the patient is opioid-naïve.
- **Example (Florida):**
  Florida restricts initial opioid prescriptions for acute pain to a 3-day supply, with an exception for a 7-day supply if medically necessary and documented. Broader exemptions often exist for chronic pain, cancer treatment, or palliative care.
  - **Clinical Implication:**
    Prescribers must be aware of and strictly adhere to these state-specific limitations to avoid legal and professional repercussions. This often necessitates careful patient counselling on why a smaller quantity is being prescribed and when refills, if appropriate, can be obtained.

- **Telemedicine Laws (Beyond Federal DEA Rules):**
  - **Patient-Prescriber Relationship:**
    Many states have specific requirements for establishing a legitimate patient-prescriber relationship via telemedicine, which can include mandates for an initial in-person evaluation before prescribing controlled substances, especially for Schedule II opioids. While federal waivers during the PHE provided flexibility, states may re-impose or strengthen these.
  - **Licensure and DEA Registration Across State Lines:**
    A critical and often complex requirement is that practitioners typically must hold a valid professional license *and* a DEA registration in *each state where they are providing care* (i.e., where the patient is physically located during the

telemedicine visit), even if the prescriber is located in a different state.

- **Clinical Implication:**
  This complexity significantly impacts the scope of practice for telemedicine providers. They must meticulously research and comply with the laws of both their originating state and the patient's location to ensure legal and ethical prescribing, especially for controlled substances.



III. Telemedicine Flexibilities and Controlled Substances

The advent of the COVID-19 Public Health Emergency (PHE) in the U.S. necessitated rapid changes in healthcare delivery, including an expansion of telemedicine services. This led the Drug Enforcement Administration (DEA) to issue temporary waivers to the **Ryan Haight Online Pharmacy Consumer Protection Act of 2008**, which generally required an in-person medical evaluation before prescribing controlled substances via the internet. The current situation is a transitional period, moving towards a more permanent regulatory framework.

- **COVID-Era Flexibilities Extended:**
  - **Provision:**
    During the PHE, the DEA issued waivers that allowed DEA-registered practitioners to prescribe **all schedules of controlled substances (Schedules II-V)** via audio-visual telehealth (two-way, real-time interactive communicat - ion) without a prior in-person medical examination.
  - **Current Status:**
    These temporary flexibilities have been extended multiple times and are currently authorised to continue **until December 31, 2025**. This extension aims to ensure a smooth transition for patients and providers who have come to rely on telemedicine for controlled medication prescriptions while the DEA finalises its permanent rules.
  - **Clinical Implication:**
    For U.S. practitioners, this extension means they can largely continue their current practice of prescribing controlled substances via telehealth for

new and existing patients without an initial in-person visit, provided they adhere to all other federal and state laws, including the "legitimate medical purpose" requirement.

- **Special Telemedicine Rule (Proposed for 2025 and beyond):**
  - **Background:**
    The Ryan Haight Act envisioned a "special registration" pathway for telemedicine prescribing of controlled substances without an in-person evaluation, but this pathway was never fully implemented until now. The DEA has been working on proposed rules to establish this permanent framework.
  - **Proposed Framework (Key Elements as of early 2025):**
    The DEA has released new proposed and final rules that outline how controlled substances can be prescribed via telemedicine after the current flexibilities expire. These are still subject to further review and public comment, but the direction is clearer:
- **Special Registration Requirement:**
  The DEA proposes to establish a **new, separate "special registration"** for practitioners who wish to prescribe controlled substances via telemedicine *without a prior in-person medical evaluation*. This would entail a new application process (e.g., Form 224S) and potentially a fee.
- **Schedule III-V Prescribing:**
  The proposed rules generally aim to **allow Schedule III-V controlled substances** (which include many common medications for anxiety, insomnia, ADHD, and some pain medications like buprenorphine for OUD) to be prescribed via telehealth *after* obtaining this special registration.
- **Schedule II Medications (e.g., Methadone):**
  Prescribing **Schedule II medications** (such as most opioid pain medications, stimulants like Adderall/Ritalin, and methadone for pain or OUD) via telemedicine *without a prior in-person medical evaluation* would generally be **more restricted** under the proposed permanent rules. Likely, these medications would often **require an in-person visit** before initial telemedicine prescribing, or be limited to specific circumstances (e.g., in a DEA-registered clinic or hospital setting, or with specific "advanced" special registrations for certain specialists). Methadone for OUD, in particular, has traditionally been highly regulated and administered in Opioid Treatment Programs (OTPs) with in-person requirements.
  - **Clinical Implication:**
    If finalised as proposed, this would

introduce a new administrative layer for telemedicine providers who wish to prescribe controlled substances without an in-person visit. It would create differentiated rules based on the schedule of the controlled substance, potentially limiting telemedicine access for some of the highest-risk medications (Schedule II).

- **Buprenorphine Exception (for OUD Treatment):**
  - **Context:**
    Buprenorphine, a Schedule III controlled substance used for Opioid Use Disorder (OUD) treatment, has received special consideration due to the urgency of the opioid crisis.
  - **Provision:**
    A specific **final rule** has been issued that allows buprenorphine for OUD to **continue to be prescribed via telemedicine or phone (audio-only)** for patients who were **established before November 11, 2023**, even without a prior in-person exam. This rule allows for an initial supply (e.g., up to 6 months) via telehealth, though ongoing PDMP checks and eventually an in-person evaluation might be required for continued prescribing beyond specific periods (e.g., 6 months).
  - **Clinical Implication:**
    This exception ensures continued access to critical OUD treatment via telehealth, acknowledging the unique public health imperative of expanding buprenorphine access and the challenges patients face in accessing in-person care. It provides a more permissive pathway for buprenorphine compared to other Schedule III-V substances under the general proposed special registration framework.

<u>Ensure Telemedicine Platforms Comply with HIPAA and DEA Requirements:</u>

- **HIPAA (Health Insurance Portability and Accountability Act):**
  All telemedicine platforms used for patient care must be **HIPAA compliant**, meaning they must implement robust technical, administrative, and physical safeguards to protect Protected Health Information (PHI). This includes secure video conferencing, encrypted data transmission, and business associate agreements (BAAs) with technology vendors.
- **DEA Requirements:**
  Telemedicine platforms, especially if they are involved in the dispensing or facilitation of controlled substance prescriptions, may also need to comply with specific DEA requirements. The proposed "Special Telemedicine Rule" includes provisions for

"Telemedicine Platform Registration," which would authorise qualified online telemedicine platforms that demonstrate a legitimate need to facilitate the prescribing and dispensing of controlled substances, subjecting them to specific security and reporting standards.

- **Clinical Implication:**
  Practitioners using telemedicine must ensure their chosen platform and workflows meet these stringent federal privacy and security standards, in addition to state-specific telemedicine regulations. Failure to do so can lead to significant legal penalties and data breaches.

The U.S. is transitioning from broad COVID-era telemedicine flexibilities for controlled substances to a more structured, permanent framework. This new framework will likely require special DEA registrations for telemedicine prescribing without an in-person exam, with potentially stricter rules for Schedule II substances, while continuing to prioritise buprenorphine access for OUD. All stakeholders, including clinicians and telemedicine platforms, must remain vigilant in ensuring compliance with evolving federal and state regulations.

IV. Clinical Implications and Practice Integration

1. Expanded Access to Buprenorphine

- **Impact:**
  Clinicians, including primary care providers and NPs, can integrate buprenorphine prescribing into routine practice, reducing stigma and enhancing treatment reach.
- **Barrier:**
  Some pharmacies may resist dispensing buprenorphine, requiring provider advocacy and education.

2. Enhanced Provider Education

- **Content Areas Covered:**
  - Safe opioid prescribing
  - Screening and brief interventions (e.g., SBIRT, ORT)
  - MAT protocols
  - Naloxone prescribing
  - Motivational interviewing
- **Evidence:**
  Studies show up to a **15% reduction** in unsafe opioid prescribing following targeted SUD training (Health Affairs, 2020).

3. Improved Patient Safety and Equity

- **Focus:**
  Training addresses cultural humility and health equity, combating disparities in MAT access (notably among minority and rural populations).
- **Tools to Use:**
  - **PDMP checks**
  - **COWS scoring**

- **Treatment agreements**
- **Naloxone co-prescribing**

4. Telehealth as an Access Multiplier

- **Benefit:**
  Telehealth increases treatment retention and continuity (20% improvement, JAMA 2021).
- **Risk:**
  Potential loss of access post-2025 if federal flexibilities expire without appropriate transition planning.

V. Best Practices for Clinician Compliance

ACTION	WHY IT MATTERS?
Complete the 8-hour SUD training	Mandatory under the MATE Act for all DEA-registered prescribers
Use PDMPs regularly	Detects misuse /diversion, ensures prescribing accountability
Incorporate naloxone co-prescribing	Reduces overdose risk and aligns with CDC guidelines
Apply risk stratification tools	Tailor opioid therapy based on individual patient risk
Document treatment plans and agreements	Supports informed consent, compliance, and medicolegal safety
Check state-specific laws	Avoids noncompliance, particularly with telemedicine and PDMP regulations

The Medication Access and Training Expansion (MATE) Act marks a significant advancement in addressing the opioid epidemic by removing prescribing barriers through the elimination of the X-waiver, mandating essential education on substance use disorders (SUDs), and reinforcing responsible controlled substance prescribing practices. By empowering clinicians to expand access to treatment and improve patient outcomes, the Act necessitates successful implementation through compliance with training requirements, continuous awareness of evolving state-specific laws, and strict adherence to best practices in opioid stewardship. With over 2.7 million Americans affected by opioid use disorder (OUD), proactive engagement with the MATE Act provisions is essential to transforming patient care and ultimately saving lives.

CONCLUSION

Safe and ethical prescribing of controlled substances requires a clear understanding of both clinical responsibilities and regulatory mandates. The **Medication Access and Training Expansion (MATE) Act** represents a pivotal shift in prescriber accountability, mandating foundational training to ensure that all DEA-registered clinicians possess the knowledge necessary to manage opioid prescribing responsibly.

This module has equipped learners with the ability to **interpret federal legislation**, particularly the MATE Act, and to integrate **structured opioid risk assessment practices**, such as informed consent, documentation, and patient-centred communication. By utilising **risk mitigation tools** like PDMPs, opioid treatment agreements, and naloxone co-prescribing, clinicians are better prepared to balance therapeutic benefit with patient safety.

Moreover, understanding the **legal and ethical dimensions of prescribing,** including scope of practice, DEA authority, and diversion prevention, ensures compliance, minimises liability, and upholds the highest standards of professional accountability. With this integrated knowledge, providers are empowered to make informed, compassionate decisions that align with current regulations and best practices in opioid stewardship.

REFERENCES

1. American College of Physicians (ACP). (2020). *Nonopioid pharmacologic treatment of chronic pain: A clinical guideline*. https://www.acponline.org
2. American Medical Association (AMA). (2023). *AMA opioid task force progress report*. https://www.ama-assn.org/delivering-care/opioids
3. American Society of Addiction Medicine (ASAM). (2023). *National practice guideline for the treatment of opioid use disorder – 2023 update*. https://www.asam.org/quality-care/clinical-guidelines
4. Centres for Disease Control and Prevention (CDC). (2022). *Clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recommendations and Reports*, 71(3), 1–95. https://www.cdc.gov/mmwr
5. Centres for Disease Control and Prevention (CDC). (2024). *Drug overdose deaths in the United States, 2023*. https://www.cdc.gov
6. Centres for Medicare & Medicaid Services (CMS). (2023). *Medicare Part D opioid policies*. https://www.cms.gov
7. DEA Diversion Control Division. (2023). *Practitioner's manual for controlled substance prescribing*. https://www.deadiversion.usdoj.gov
8. Federation of State Medical Boards (FSMB). (2023). *Model policy for the use of controlled substances for the treatment of pain*. https://www.fsmb.org
9. Health Affairs. (2020). *Impact of clinician training on safer opioid prescribing*. https://www.healthaffairs.org
10. National Academies of Sciences, Engineering, and Medicine. (2019). *Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use*.

https://nap.nationalacademies.org/catalog/24781

11. National Institute on Drug Abuse (NIDA). (2024). *Opioid overdose crisis: Current trends and statistics*. https://nida.nih.gov/publications/research-reports/opioids

12. Substance Abuse and Mental Health Services Administration (SAMHSA). (2023). *Medication Access and Training Expansion (MATE) Act overview*. https://www.samhsa.gov

13. U.S. Department of Health and Human Services (HHS). (2023). *Pain management best practices: Updates from the HHS task force*. https://www.hhs.gov/opioids/

14. U.S. Department of Justice, DEA. (2024). *Frequently asked questions about the MATE Act*. https://www.deadiversion.usdoj.gov

15. Wakeman, S. E., & Barnett, M. L. (2023). Opioids and the MATE Act: A national strategy for safer prescribing. *New England Journal of Medicine*, 388(6), 1234–1242. https://doi.org/10.1056/NEJMp2215246